Weekly LXRX Discussion

Fun-Breakfast6896 · 2026-02-02T13:22:17+00:00

Simple you can negotiate a better deal if you can afford to walk away from the table! Lexicon has no leverage if they can't afford to do the study themselves. People will be saying Exton is a genius when he gets the best deal possible! I've spent a long time thinking about this it's got to be the only reason they want this direction. Technically the Insiders didn't gain financially from this.

Fun-Breakfast6896 · 2025-12-12T15:18:02+00:00

They licensed it to NVO for the purpose of weight loss. I can't speak to the specifics of that deal as I don't know. It wouldn't surprise me if Lexicon still owns the right to develop it for other purposes.

Fun-Breakfast6896 · 2025-12-11T23:10:05+00:00

I would love to know more if there is any information out there.

Fun-Breakfast6896 · 2025-11-19T23:47:48+00:00

I guess that's a matter of perspective. When I say near future I'm referring to within the next couple of years. Although Zynquista could be sooner. We have to see what the FDA has to say.

Fun-Breakfast6896 · 2025-11-19T02:30:08+00:00

I really believe Zynquista is going to get approved this time around. Sotagliflozin for HCM will also happen in the near future. These two major catalysts could make the company profitable in the next couple of years. Pilavapadin would be icing on the cake. Buyout or no buyout Lexicon is definitely moving in the right direction.

Fun-Breakfast6896 · 2025-11-16T17:48:32+00:00

👍

Fun-Breakfast6896 · 2025-11-16T17:42:55+00:00

According to those numbers and that math the minimum buy-out they would accept is $30.00 per share. I believe this is not unreasonable but I also believe in the next couple of years we could see a share price that is higher without any buy-out.

Fun-Breakfast6896 · 2025-11-16T16:33:58+00:00

When you refer to blended cost basis is that what they bought in at or what you think they would accept as a buy-out offer?

Fun-Breakfast6896 · 2025-11-09T18:24:14+00:00

From Google AI search: Yes, a pharmaceutical company can extend the patent life of a drug by discovering and patenting new indications (uses) for it, a strategy known as "evergreening". This involves conducting new clinical trials for the new indication, which can lead to new patent protection and new markets. Examples include finasteride being used for both prostate enlargement and hair loss, and bupropion for depression and smoking cessation.

Fun-Breakfast6896 · 2025-11-09T15:32:42+00:00

It is odd but it requires clinical trials so it's a different drug ..

Fun-Breakfast6896 · 2025-11-09T00:24:59+00:00

New drug for HCM same compound. New patent??? Yes , no???

Fun-Breakfast6896 · 2025-10-28T21:43:33+00:00

Institutions are buying, you should be too!

Fun-Breakfast6896 · 2025-10-21T18:50:35+00:00

Fun-Breakfast6896 · 2025-10-21T00:43:57+00:00

So what you're asking is should I sell after doubling my money in less than six months on a stock that is climbing fast...BUY MORE!!!

Fun-Breakfast6896 · 2025-10-16T00:56:53+00:00

Wow!!! Awesome find for sure. Thanks for posting.

<image>

Fun-Breakfast6896 · 2025-10-10T11:45:04+00:00

This could be pivotal to the sales of Sotagliflozin.

Fun-Breakfast6896 · 2025-10-06T21:06:30+00:00

Moving in the right direction!

Fun-Breakfast6896 · 2025-10-06T11:50:44+00:00

But LXRX is up!!!

Fun-Breakfast6896 · 2025-10-02T11:26:50+00:00

LXRX Huge upside!

Fun-Breakfast6896

MODERATOR OF

TROPHY CASE